On August 25, WUXI BIO rose 3.81% in regular trading, trading at 50.3 HKD/share, with turnover of 681 million HKD. The rally came as the company's board convened to review interim results, while the broader CXO sector staged a collective rally.

The CXO sector saw strong gains across the board, with peer WUXI XDC surging 8.52%, GenScript Biotech rising 6.07%, and Pharmaron gaining 1.03%. WUXI XDC reported interim revenue of 3.701 billion yuan, representing 37% year-over-year growth, with unfilled orders exceeding $2 billion, further validating the sector's upward momentum in business activity. Additionally, Moderna's mRNA cancer vaccine achieving its primary endpoint in a Phase III clinical trial continued to catalyze positive sentiment across the biopharmaceutical sector.

Industry research indicates that the CXO sector has entered a new recovery upcycle characterized by both domestic and international demand resonance, new molecular platform volume expansion, and sequential improvement in orders and earnings. Global biopharma financing has rebounded significantly, with first-half deal volume reaching $99.7 billion in China-related transactions, reinforcing the sector's growth visibility.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)